TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26637828

Group type: EXPERIMENTAL
Intervention: Girls experiencing IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boys perpetrating IPV
Number of subjects: 0
Study: 25066019

Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity (SBS-PA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unstructured playtime (UPA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SBS-PA and UPA
Number of subjects: 10
Study: 22825948

Group type: EXPERIMENTAL
Intervention: LVFWR group (49 patients)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Non-LVFWR group (221 patients)
Number of subjects: 270
Study: 19417866

Group type: EXPERIMENTAL
Intervention: 30% carbamide peroxide with 5% potassium nitrate (treatment A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30% carbamide peroxide without potassium nitrate (treatment B)
Number of subjects: 40
Study: 17690311

Group type: EXPERIMENTAL
Intervention: Early decompressive craniectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: No surgery (medical therapy only)
Number of subjects: 38
Study: 15031622

Group type: EXPERIMENTAL
Intervention: Sono-guided endometrial biopsy (SH-EB) using a 3.1-mm ultrasound-guided Bernard catheter
Number of subjects: 105

Group type: COMPARATOR
Intervention: Endometrial biopsy after hysteroscopy (HSC-EB) using a Cornier Pipelle
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comparison of endometrial thickness
Number of subjects: 105
Study: 11579707

Group type: EXPERIMENTAL
Intervention: Methotrexate (starting at 7.5 mg/week, max 20 mg/week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9701736

Group type: EXPERIMENTAL
Intervention: Percutaneous suprapubic transvesical route (STR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Transperineal route (TPR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: STR
Number of subjects: 37

Group type: COMPARATOR
Intervention: TPR
Number of subjects: 37
Study: 7493231

Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intraocular pressure regulation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pilocarpine vs laser trabeculoplasty
Number of subjects: 82
Study: 1965007

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amphotericin-B
Number of subjects: 40

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 40
Study: 759142

Group type: EXPERIMENTAL
Intervention: Sandovac 1000
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sandovac 2000
Number of subjects: 104
Study: 31724377

Group type: EXPERIMENTAL
Intervention: PTSD and PTG assessment using geographic information systems analyses
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Geographic information systems analyses
Number of subjects: 171
Study: 27647837

Group type: EXPERIMENTAL
Intervention: Hypocaloric, low-glycaemic, low-saturated fat diet and physical activity recommendations
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard Care (lifestyle advice regarding healthy nutrition and exercise)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Both groups (adherent women)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 191
Study: 26166166

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (OctLAR) 40 mg monthly
Number of subjects: 28

Group type: COMPARATOR
Intervention: Off therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (OctLAR)
Number of subjects: 28
Study: 24814320

Group type: EXPERIMENTAL
Intervention: Humor therapy sessions provided by professional 'ElderClowns' (9 to 12 weekly sessions)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 398
Study: 23214253

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (antibiotics plus hemostatics with usual wound care)
Number of subjects: 84
Study: 19107591

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ADHD (regardless of medication)
Number of subjects: 75
Study: 17785752

Group type: EXPERIMENTAL
Intervention: ABTrans autologous retransfusion system
Number of subjects: 158

Group type: COMPARATOR
Intervention: Two vacuum drains
Number of subjects: 158
Study: 15177825

Group type: EXPERIMENTAL
Intervention: Cocaine-exposed group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 12271412

Group type: EXPERIMENTAL
Intervention: Potassium iodide (KI) 100 mg per day starting 2 days before (131)I-lipiodol administration and continuing until 2 weeks after therapy; n=31
Number of subjects: 68

Group type: COMPARATOR
Intervention: No potassium iodide (non-KI group); n=37
Number of subjects: 68
Study: 9805727

Group type: EXPERIMENTAL
Intervention: New programme of antenatal care
Number of subjects: 53

Group type: COMPARATOR
Intervention: Current programme in use
Number of subjects: 53
Study: 7715639

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 2651248

Group type: EXPERIMENTAL
Intervention: Dosulepin (Idom) 75 mg daily in the evening
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 520386

Group type: EXPERIMENTAL
Intervention: Hydergine‐Sandoz (ergot alkaloids)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31840388

Group type: EXPERIMENTAL
Intervention: Prophylactic oral antiviral use pre- and post-treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Post-treatment sun protection
Number of subjects: 58
Study: 30421864

Group type: EXPERIMENTAL
Intervention: Prenatal intervention with meal replacements
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study: 28399483

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) intervention to incentivize safe sex
Number of subjects: 20
Study: 26331550

Group type: EXPERIMENTAL
Intervention: rhIGF-I (120 μg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 23935959

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22609501

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 25 microgram/kg/min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 50 microgram/kg/min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 75 microgram/kg/min
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 19146991

Group type: EXPERIMENTAL
Intervention: Plausible value imputation (PVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent marginal maximum likelihood (MML)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited information two-step marginal maximum likelihood method
Number of subjects: 0
Study: 16710252

Group type: EXPERIMENTAL
Intervention: Combination of perindopril (2 mg) and indapamide (0.625 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Monotherapy with enalapril (10 mg)
Number of subjects: 72
Study: 16968506

Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation with BIS visible (Phase 1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation with BIS visible (Phase 2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (Phase 1)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (Phase 2)
Number of subjects: 102
Study: 14567499

Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blocker (ARB: valsartan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I: temocapril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting Ca antagonists (L- and N-type Ca channel blocker: cilnidipine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-type Ca channel blocker (nifedipine CR)
Number of subjects: 0
Study: 10423075

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine, with possible addition of enalapril and hydrochlorothiazide)
Number of subjects: 4695
Study: 8655368

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (BEC regimen)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 339
Study: 1796409

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6351587

Group type: EXPERIMENTAL
Intervention: Oral tyrosine (7.5 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral tryptophan (3 g/day)
Number of subjects: 0
Study: 30314504

Group type: EXPERIMENTAL
Intervention: Moisturising oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study: 28719062

Group type: EXPERIMENTAL
Intervention: Immersive VR interactive model
Number of subjects: 66

Group type: COMPARATOR
Intervention: Online textbooks
Number of subjects: 66
Study: 25098596

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) combined with chest physical therapy (CPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional standard chest physical therapy (CPT)
Number of subjects: 20
Study: 23177921

Group type: EXPERIMENTAL
Intervention: Interactive video-game based (IVGB) training for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (first 6 weeks) followed by IVGB training (next 6 weeks)
Number of subjects: 30
Study: 22321885

Group type: EXPERIMENTAL
Intervention: Palonosetron (drug A)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Tropisetron (drug B)
Number of subjects: 155
Study: 18192922

Group type: EXPERIMENTAL
Intervention: Rapamycin (RAPA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Number of subjects: 18
Study: 16441782

Group type: EXPERIMENTAL
Intervention: Subgingival plaque samples from peri-implant pockets
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cultural techniques
Number of subjects: 42
Study: 15110922

Group type: EXPERIMENTAL
Intervention: PMDD patients during the follicular phase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Symptom-free controls during the follicular phase
Number of subjects: 28
Study: 11122727

Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9315523

Group type: EXPERIMENTAL
Intervention: Simvastatin and low-cholesterol diet
Number of subjects: 72
Study: 8233296

Group type: EXPERIMENTAL
Intervention: Radiotherapy and simultaneous carboplatin (60 or 70 mg/m2 from days 1‐5 and 29‐33) with a fractionation of 5 x 2 Gy/week up to a dose of 50 Gy.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/day, 5 days per week: total dose, 64‐67.2 Gy) and simultaneous intravenous carboplatin (60 mg/m2, days 1‐5 and 29‐33).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional radiotherapy with carboplatin (not detailed in the abstract).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyperfractionated accelerated irradiation with carboplatin (not detailed in the abstract).
Number of subjects: 100
Study: 3518183

Group type: EXPERIMENTAL
Intervention: Prophylactic carbenicillin indanyl sodium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29412521

Group type: EXPERIMENTAL
Intervention: Endobronchially administered adipose-derived stem cells (ADSCs)
Number of subjects: 14
Study: 26483047

Group type: EXPERIMENTAL
Intervention: bevacizumab (wt-B)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: bevacizumab + erlotinib (wt-BE)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: bevacizumab (mut-B)
Number of subjects: 233

Group type: COMPARATOR
Intervention: metronomic capecitabine (mut-C)
Number of subjects: 233
Study: 25123600

Group type: EXPERIMENTAL
Intervention: Zonisamide 200 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Zonisamide 400 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 21553144

Group type: EXPERIMENTAL
Intervention: Intervention group (DMIE program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20116047

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral capsule/ventral striatum
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 6
Study: 18683781

Group type: EXPERIMENTAL
Intervention: Energetic nutritional intervention (caloric supplementation for at least 2 weeks)
Number of subjects: 354
Study: 15864805

Group type: EXPERIMENTAL
Intervention: Intravascular radiation therapy (IRT) with iridium (Ir)-192 (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonradioactive seeds (n = 60)
Number of subjects: 120
Study: 14581404

Group type: EXPERIMENTAL
Intervention: Intense and prolonged exercise
Number of subjects: 20
Study: 11026883

Group type: EXPERIMENTAL
Intervention: Information and choice group
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Standard practice (control) group
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Information and choice group (infected women)
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Standard practice (control) group (infected women)
Number of subjects: 2107
Study: 8860277

Group type: EXPERIMENTAL
Intervention: Community participation (Trial 1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Family physician involvement (Trial 2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Community participation (Trial 2)
Number of subjects: 8
Study: 1704837

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6510013

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg) taken before food
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg) taken after food
Number of subjects: 663
Study: 28810385

Group type: EXPERIMENTAL
Intervention: General exercise recommendation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Specific exercise recommendation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 29730838

Group type: EXPERIMENTAL
Intervention: Thulium vapoenucleation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 94
Study: 27191689

Group type: EXPERIMENTAL
Intervention: Bortezomib-PLD (bortezomib plus pegylated liposomal doxorubicin 30 mg/m² intravenously on day 4)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Bortezomib alone (1.3 mg/m² intravenously on days 1, 4, 8, and 11 of every 21-day cycle)
Number of subjects: 646
Study: 24803644

Group type: EXPERIMENTAL
Intervention: VR group (n=11) received nine 30 minutes upper extremity VR therapy in standing plus conventional therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (n=12) received only conventional therapy
Number of subjects: 23
Study: 22695205

Group type: EXPERIMENTAL
Intervention: EUS‐FNA with a stylet
Number of subjects: 100

Group type: COMPARATOR
Intervention: EUS‐FNA without a stylet
Number of subjects: 100
Study: 20827179

Group type: EXPERIMENTAL
Intervention: Noninvasive recognition of diastolic dysfunction during stress testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of diastolic dysfunction
Number of subjects: 0
Study: 18602155

Group type: EXPERIMENTAL
Intervention: Traffic background noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Babble background noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 0
Study: 16091787

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12614450

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study: 10741815

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS-11)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal Rating Scale (VRS-4)
Number of subjects: 0
Study: 8637302

Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronchodilator use
Number of subjects: 0
Study: 1300205

Group type: EXPERIMENTAL
Intervention: Multiple-dose, combination-drug clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory procedure based on RSM modeling
Number of subjects: 0
Study: 3970796

Group type: EXPERIMENTAL
Intervention: Suggestion group (patients exposed to statements about touching their ear)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Suggestion group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 30031593

Group type: EXPERIMENTAL
Intervention: Cooling temperature of 18 °C
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cooling temperature of 22 °C
Number of subjects: 36
Study: 26420821

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (10 sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 30
Study: 24612447

Group type: EXPERIMENTAL
Intervention: Advice to remain active
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice to rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy after a seven week waiting list
Number of subjects: 0
Study: 22245235

Group type: EXPERIMENTAL
Intervention: Soybean oil based lipid emulsion (Intralipid®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Olive oil based lipid emulsion (Clinoleic®)
Number of subjects: 40
Study: 20968113

Group type: EXPERIMENTAL
Intervention: High polyphenol chocolate (45 g daily for 8 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low polyphenol chocolate (45 g daily for 8 weeks)
Number of subjects: 12
Study: 18552464

Group type: EXPERIMENTAL
Intervention: Interferon-beta therapy (6 MU daily for 6 or 8 weeks)
Number of subjects: 25
Study: 15872029

Group type: EXPERIMENTAL
Intervention: bezafibrate retard 400 mg once daily
Number of subjects: 339

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: triglycerides (50 mg/dL increment)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: fasting glucose (10 mg/dL increment)
Number of subjects: 339
Study: 12431899

Group type: EXPERIMENTAL
Intervention: Extracurricular activities intervention
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 3028
Study: 12079015

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine 150 mg + morphine 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine 150 mg + morphine 4 mg + methylprednisolone 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular saline
Number of subjects: 60
Study: 9785106

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg once daily for 7 days
Number of subjects: 451

Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 7 days
Number of subjects: 451
Study: 7696786

Group type: EXPERIMENTAL
Intervention: Continuous, warm, noncardioplegic retrograde blood perfusion (n = 37)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Antegrade perfusion
Number of subjects: 66
Study: 2169701

Group type: EXPERIMENTAL
Intervention: Mycoprotein
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control diet (meat)
Number of subjects: 2
Study: 353682

Group type: COMPARATOR
Intervention: Methylprednisolone sodium succinate intravenously, 30 mg/sq m every six hours (conventional dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate intravenously, 300 mg/sq m every six hours (high dose)
Number of subjects: 21
Study: 7168176

Group type: EXPERIMENTAL
Intervention: 50 mcg sulprostone administered intramurally into the cervix
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 4 injections of 250 micrograms sulprostone administered intragluteally at 4 hour intervals
Number of subjects: 154
Study: 29913227

Group type: EXPERIMENTAL
Intervention: High-intensity light (9000 lx)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-intensity light (<500 lx)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 29
Study: 26285057

Group type: EXPERIMENTAL
Intervention: MR perfusion studies
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Duke jeopardy score
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Poor image quality, triple-vessel disease, inadequate hemodynamic response
Number of subjects: 265
Study: 24880345

Group type: EXPERIMENTAL
Intervention: Collagen hemostat (COLL)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Carrier-bound fibrin sealant (CBFS)
Number of subjects: 128
Study: 22983408

Group type: EXPERIMENTAL
Intervention: Maternal counseling based on Motivational Interviewing (MI) delivered during pregnancy and at well-baby visits.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (no MI-style counseling).
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Maternal counseling based on Motivational Interviewing (MI) with 4 or more sessions.
Number of subjects: 272
Study: 20395129

Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy
Number of subjects: 443

Group type: COMPARATOR
Intervention: Standard doublet regimen
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy in adenocarcinomas
Number of subjects: 443